Quantcast
Last updated on April 19, 2014 at 1:20 EDT

Latest Medicago Inc. Stories

2013-06-11 08:30:28

QUEBEC CITY, June 11, 2013 /PRNewswire/ - Medicago Inc. (TSX: MDG; OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced it has received clearance by Health Canada to initiate its Phase II dose-sparing clinical trial for an H5N1 Avian Influenza VLP vaccine candidate ("H5N1 vaccine"). All clinical lots have been produced and the trial...

2013-06-06 08:29:08

- The H7 VLP vaccine candidate induces an antibody response after a single dose in mice- QUEBEC CITY, June 6, 2013 /PRNewswire/ - Medicago Inc. (TSX: MDG; OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today reported positive interim results from a preclinical trial for an H7N9 Avian Influenza VLP vaccine candidate ("H7 vaccine"). The data show...

2013-05-08 08:29:35

-Medicago Ready to Collaborate with Authorities to Further Study the Potential of this Vaccine to Protect Against H7N9- QUEBEC CITY, May 8, 2013 /PRNewswire/ - Medicago Inc. (TSX: MDG; OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it has successfully produced a new VLP vaccine candidate  for the H7N9 virus that is...

2013-04-18 10:04:12

All 3 configurations of adjuvant and route of administration exceeded the 3 CHMP criteria IDRI (Infectious Disease Research Institute), a Seattle-based non-profit research organization that is a leading developer of adjuvants used in vaccines combating infectious disease, and Medicago Inc. (TSX: MDG; OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs),...

2013-04-17 16:25:56

- All three configurations of adjuvant and route of administration exceeded the three CHMP criteria- QUEBEC CITY, and SEATTLE, WA, April 17, 2013 /PRNewswire/ - Medicago Inc. (TSX: MDG; OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs) and The Infectious Disease Research Institute (IDRI), a Seattle-based non-profit research organization that is a...

2013-04-17 16:25:53

- All three configurations of adjuvant and route of administration exceeded the three CHMP criteria- SEATTLE and QUEBEC CITY, April 17, 2013 /PRNewswire-USNewswire/ -- IDRI (Infectious Disease Research Institute), a Seattle-based non-profit research organization that is a leading developer of adjuvants used in vaccines combating infectious disease, and Medicago Inc. (TSX: MDG; OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based...

2013-04-09 08:29:23

-Presentation of Positive Interim Phase I Clinical Trial results for an H5N1 Vaccine with GLA Adjuvant- QUEBEC CITY, and SEATTLE, WA, April 9, 2013 /PRNewswire/ - Medicago Inc. (TSX: MDG); (OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs) and, IDRI (Infectious Disease Research Institute), a Seattle-based non-profit research organization that is a...

2013-04-09 08:29:06

Presentation of Positive Interim Phase I Clinical Trial results for an H5N1 Vaccine with GLA Adjuvant SEATTLE and QUEBEC CITY, April 9, 2013 /PRNewswire/ -- IDRI (Infectious Disease Research Institute), a Seattle-based non-profit research organization that is a leading developer of adjuvants used in vaccines combating infectious disease, and Medicago Inc. (TSX: MDG; OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines...

2013-03-28 16:25:14

QUEBEC CITY, March 28, 2013 /PRNewswire/ - Medicago Inc. (TSX: MDG), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced its operational and financial results for the fourth quarter and year ended December 31, 2012. The Company's financial statements and management report are available at www.sedar.com and at www.medicago.com. "2012 was a...

2013-02-26 08:28:37

QUEBEC CITY, Feb. 26, 2013 /PRNewswire/ - Medicago Inc. (TSX: MDG; OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that the Company will be presenting at the following upcoming U.S. investor conferences. RBC Capital Markets 2013 Healthcare Conference - The conference is being held February 26-27, 2013 at the New York Place, New...